Boyds, a leading consultancy business supporting the development of pharmaceutical and biotech products for patient benefit, has announced a key appointment in support of its continued growth plans.

Dr Sabine Rühle joins Boyds as Senior Associate of Regulatory Affairs and will be based at Boyds’ Cambridge offices, which opened last year.  

A member of the Organisation of Professionals in Regulatory Affairs (MTOPRA), Sabine joins from Pharmaceutical Product Development, where she was Senior Regulatory Affairs Specialist and coordinated global CTA submissions for a variety of products and therapeutic indications. She was also a member of PPD’s Advanced Therapy Forum and worked on advanced therapy product development.

Prior to this, Sabine studied Biochemistry at the University of Bayreuth, Germany before completing a PhD in Natural Sciences at Johannes Gutenberg University Mainz. She then worked as a postdoctoral researcher at both the MRC Lab of Molecular Biology, Cambridge and the Sainsbury Wellcome Centre for Neural Circuits and Behaviour at University College London.

Sabine said: “The team at Boyds is committed to advancing the development of life changing treatment options and has expertise in advanced therapies, which is an area I am particularly passionate about.

“In my new role, I will be working on regulatory document preparation, as well as providing project and operational support to sponsors in all stages of drug development. 

“I am looking forward to drawing on my scientific background and knowledge of Advanced Therapy Medicinal Products, as well as learning from the experts at Boyds.”

Boyds Founder and CEO, Professor Alan Boyd, said, “Boyds is currently going through a period of significant growth, and demand for our regulatory services is high.

“I am delighted to welcome Sabine to the team at this exciting time. Sabine brings a wealth of knowledge and experience in both preclinical research and regulatory affairs, which will be of great value to our clients.”